Evidence map›Paper›PMID 42449919›Full record

ArticleInternational journal of molecular sciences2026

Ruifang Zheng, Yanwen Du, Shoubao Wang, Wenling Su, Kaderyea Kader, Lijuan Zhang, Zihan Wang, Diwei Liu, Jianguo Xing, Shifeng Chu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruifang ZhengSchool of Preclinical Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Yanwen DuXinjiang Key Laboratory of Uygur Medical Research, Xinjiang Institute of Materia Medica, Urumqi 830004, China.
Shoubao WangBeijing Key Laboratory for Novel Drugs Discovery and Crystal Form Research in Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Wenling SuXinjiang Key Laboratory of Uygur Medical Research, Xinjiang Institute of Materia Medica, Urumqi 830004, China.
Kaderyea KaderXinjiang Key Laboratory of Uygur Medical Research, Xinjiang Institute of Materia Medica, Urumqi 830004, China.
Lijuan ZhangXinjiang Key Laboratory of Uygur Medical Research, Xinjiang Institute of Materia Medica, Urumqi 830004, China.
Zihan WangBeijing Key Laboratory for Novel Drugs Discovery and Crystal Form Research in Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Diwei LiuXinjiang Key Laboratory of Uygur Medical Research, Xinjiang Institute of Materia Medica, Urumqi 830004, China.
Jianguo XingXinjiang Key Laboratory of Uygur Medical Research, Xinjiang Institute of Materia Medica, Urumqi 830004, China.
Shifeng ChuXinjiang Key Laboratory of Uygur Medical Research, Xinjiang Institute of Materia Medica, Urumqi 830004, China.
Ming XuSchool of Preclinical Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.

Funding

Central Government Guidance Funds for Local Science and Technology Development Projects of Xinjiang Uygur Autonomous Region ZYYD2026QY05National Natural Science Foundation of China 82260845National Natural Science Foundation of China 82460848Natural Science Foundation of Xinjiang Uygur Autonomous Region 2022D01D50Natural Science Foundation of Xinjiang Uygur Autonomous Region 2023D01E10the Non-profit Central Research Institute Fund of CAMS 2023-RW360-01Tianshan Talents Leading Talents in Scientific and Technological Innovation 2023TSYCLJ0042Tianshan Talent Training Program: Youth Support Talent Project 2023TSYCQNTJ0010
6 · The paper itself

Abstract

Doxorubicin (DOX) is a potent chemotherapeutic drug, whose clinical application is largely restricted by dose-dependent cardiotoxicity (DIC).

Indexed as

AMP-Activated Protein KinasesCardiotoxicityDoxorubicinFlavonoidsLamiaceaeMitochondriaPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaAnimalsApoptosisHomeostasisMyocytes, CardiacOxidative StressSignal TransductionAMP-Activated Protein KinasesDoxorubicinFlavonoidsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaAMPK/PGC1α pathwaydoxorubicin-induced cardiotoxicityfunctional foodmitochondrial damagetotal flavonoids of Dracocephalum moldavica L.

Identifiers

PMID42449919
PMCPMC13361811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.